Loading company…
Verona-based drug discovery company developing small molecule degraders that target proteins through its PPI-FIT mechanism.
Founded in Verona, Italy, Sibylla Biotech S.r.l. focuses on drug discovery and development, particularly small molecule degraders built on a mechanism called Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT). The technology applies to oncology, neurodegenerative disorders and COVID-19, and the company works with academic and pharmaceutical partners. It reported no revenue in 2023 and an EBITDA of EUR -5,523,627.1, earning income from milestone payments, licensing fees and potential royalties. The company raised EUR 23 mn in Series A funding on October 4, 2022, led by V-Bio Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in